- Trials with a EudraCT protocol (107)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
107 result(s) found for: Wet AMD AND Age-Related Macular Degeneration.
Displaying page 5 of 6.
| EudraCT Number: 2019-002738-36 | Sponsor Protocol Number: AKST4290-205 | Start Date*: 2019-10-30 | |||||||||||
| Sponsor Name:Alkahest, Inc. | |||||||||||||
| Full Title: A Double-Masked, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy of Oral AKST4290 with Loading Doses of Aflibercept in Patients with Newly Diagnosed Neovascular Age-Related Macular ... | |||||||||||||
| Medical condition: Newly Diagnosed Neovascular Age-Related Macular Degeneration | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-002302-36 | Sponsor Protocol Number: MATE2015 | Start Date*: 2018-02-06 | |||||||||||
| Sponsor Name:York Teaching Hospital | |||||||||||||
| Full Title: Treating neovascular age-related Macular Degeneration with Aflibercept:A multi-centre randomized controlled trial comparing Standard Care with an individualised Treat and Extend regimen. | |||||||||||||
| Medical condition: Neovascular Age-related macular degeneration | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-002152-32 | Sponsor Protocol Number: GR40306 | Start Date*: 2019-04-30 | |||||||||||
| Sponsor Name:F.Hoffmann La-Roche Ltd | |||||||||||||
| Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATIO... | |||||||||||||
| Medical condition: Neovascular age-related macular degeneration | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) HU (Completed) GB (GB - no longer in EU/EEA) PL (Completed) ES (Ongoing) NL (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-002503-17 | Sponsor Protocol Number: 20170542 | Start Date*: 2020-08-10 | |||||||||||
| Sponsor Name:Amgen Inc | |||||||||||||
| Full Title: A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration | |||||||||||||
| Medical condition: Neovascular Age-related Macular Degeneration | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) LV (Completed) EE (Completed) SK (Completed) ES (Ongoing) CZ (Completed) LT (Completed) PL (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-002930-19 | Sponsor Protocol Number: XBR1001 | Start Date*: 2019-02-25 | |||||||||||
| Sponsor Name:Xbrane Biopharma | |||||||||||||
| Full Title: A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane versus Lucentis® in Patients with Neovascular Age-Related Macular Degeneration | |||||||||||||
| Medical condition: Wet Age-related macular degeneration (AMD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: EE (Completed) LT (Completed) HU (Completed) SK (Completed) LV (Completed) CZ (Completed) BG (Completed) PL (Completed) ES (Ongoing) RO (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-005686-11 | Sponsor Protocol Number: SP878 | Start Date*: 2006-02-21 |
| Sponsor Name:SCHWARZ PHARMA Deutschland GmbH | ||
| Full Title: CONFIRMATORY, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUPS STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROSTAGLANDIN E1 IN SUBJECTS WITH DRY AGE-RELATED MACULAR DEGENER... | ||
| Medical condition: Patients with dry age-related macular degeneration | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-000590-93 | Sponsor Protocol Number: CR213-20 | Start Date*: 2023-06-09 | |||||||||||
| Sponsor Name:CuraTeQ Biologics Private Ltd. | |||||||||||||
| Full Title: A Phase 3, Randomized, Double-Blind, Parallel Group, Multicenter Study to Compare Efficacy, Safety, Pharmacokinetics, and Immunogenicity of BP05 Versus EU-Approved Lucentis® in Patients with Wet (N... | |||||||||||||
| Medical condition: Wet (Neovascular) Age-Related Macular Degeneration | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Trial now transitioned) LV (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-004042-42 | Sponsor Protocol Number: GR40844 | Start Date*: 2019-05-22 | |||||||||||
| Sponsor Name:F.Hoffmann La-Roche Ltd | |||||||||||||
| Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATIO... | |||||||||||||
| Medical condition: Neovascular age-related macular degeneration | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) PT (Completed) DE (Completed) HU (Completed) DK (Completed) ES (Completed) PL (Completed) BG (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-002531-15 | Sponsor Protocol Number: 09/0959 | Start Date*: 2016-11-14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:UCL Comprehensive Clinical Trials Unit | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A phase II, open label, non-randomised, single centre, clinical trial of ANX776 in Healthy Volunteers and patients with Glaucoma, Age-Related Macular Degeneration, and Optic Neuritis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Glaucoma, Age-related Macular Degeneration, and Optic Neuritis. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2004-004867-31 | Sponsor Protocol Number: EOP 1012D | Start Date*: 2005-04-12 |
| Sponsor Name:(OSI) Eyetech Pharmaceuticals, Inc | ||
| Full Title: A Phase 3B/4, randomized, active controlled, double-masked, single dummy, multi-center comparative trial, in parallel groups, to compare the safety and efficacy of intravitreous injections of Macug... | ||
| Medical condition: Exudative Age Related Macular Degeneration (AMD) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) SE (Prematurely Ended) AT (Completed) DE (Prematurely Ended) IT (Completed) ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-004767-53 | Sponsor Protocol Number: CRTH258ADE01 | Start Date*: 2020-12-16 | |||||||||||
| Sponsor Name:Novartis Pharma GmbH | |||||||||||||
| Full Title: A 52-week, two arm, randomized, open-label, multicenter study assessing the efficacy and safety of two different brolucizumab 6 mg dosing regimens for patients with suboptimal anatomically controll... | |||||||||||||
| Medical condition: neovascular age-related macular degeneration | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-005798-75 | Sponsor Protocol Number: NVI-114 | Start Date*: 2008-02-21 |
| Sponsor Name:Neo Vista Inc. | ||
| Full Title: Estudio prospectivo, aleatorizado y controlado de Epi-Rad90™, sistema oftálmico para el tratamiento de la neovascularización coroidea subfoveolar asociada a degeneración macular de tipo húmedo asoc... | ||
| Medical condition: neovascularización coroidea subfoveolar asociada a degeneración macular de tipo húmedo asociada a la edad | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-004530-11 | Sponsor Protocol Number: ALT-L9-03 | Start Date*: 2022-04-21 | |||||||||||
| Sponsor Name:Altos Biologics Inc. | |||||||||||||
| Full Title: A Randomized, Phase 3, Double Masked, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of ALT L9 Versus Eylea® in Patients With Neovascular Age Related Macular Degeneration (ALT... | |||||||||||||
| Medical condition: Neovascular Age Related Macular Degeneration | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) HU (Completed) SK (Completed) LV (Completed) AT (Completed) ES (Ongoing) BG (Completed) EE (Completed) LT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-023037-35 | Sponsor Protocol Number: LIEPS2010 | Start Date*: 2011-05-05 | ||||||||||||||||
| Sponsor Name:York Teaching Hospital NHS Foundation Trust | ||||||||||||||||||
| Full Title: Short-term intraocular pressure trends in high risk patients following intravitreal Ranibizumab (Lucentis) injections for Wet Age Related Macular Degeneration - Is there a role for systemic Acetazo... | ||||||||||||||||||
| Medical condition: Glaucoma and Glaucoma suspect | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2005-001235-30 | Sponsor Protocol Number: MSI-1256F-302 | Start Date*: 2005-10-26 |
| Sponsor Name:Genaera Corporation | ||
| Full Title: A Phase 3 Multicenter, Randomized, Double-Masked, Controlled Study of Squalamine Lactate (MSI-1256F) for Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Re... | ||
| Medical condition: Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-003517-33 | Sponsor Protocol Number: CRFB002A2302 | Start Date*: 2005-11-11 |
| Sponsor Name:Novartis Pharma Services AG | ||
| Full Title: A randomized, double-masked, active-controlled, multicenter study comparing the efficacy and safety of ranibizumab (0.3 mg and 0.5 mg) administered as two dosing regimens in patients with subfoveal... | ||
| Medical condition: Male and female patients ≥50 years of age with either with predominantly classic, minimally classic, or occult lesions with no classic component, all with primary or recurrent subfoveal CNV seconda... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: HU (Completed) AT (Completed) DE (Completed) ES (Completed) PT (Completed) GB (Completed) CZ (Completed) IT (Completed) BE (Completed) FI (Completed) SE (Completed) GR (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2008-001600-23 | Sponsor Protocol Number: HLS02/2008 | Start Date*: 2010-01-08 |
| Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE) | ||
| Full Title: Prospective, randomized, single masked pilot study on the variation of choroidal blood flow analyzed through the HRA dynamic angiography in patients treated with intravitreal injection of Selecti... | ||
| Medical condition: Choroidal neovascularization in patients with age-related macular degeneration. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: IT (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-003226-71 | Sponsor Protocol Number: MR42410 | Start Date*: 2022-01-31 | |||||||||||
| Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: A PHASE IIIB, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED STUDY OF THE EFFECTIVENESS AND SAFETY OF A 36-WEEK REFILL REGIMEN FOR THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB VS AFLIBERCEPT TREAT & ... | |||||||||||||
| Medical condition: Neovascular Age-Related Macular Degeneration (AMD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) FI (Completed) HU (Completed) DK (Completed) PT (Completed) GR (Completed) IE (Completed) NL (Completed) DE (Completed) AT (Completed) PL (Prematurely Ended) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001313-20 | Sponsor Protocol Number: WR42221 | Start Date*: 2021-10-21 | |||||||||||
| Sponsor Name:F. Hoffman-La Roche Ltd | |||||||||||||
| Full Title: A PHASE IIIb, GLOBAL, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR−MASKED STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF A 36-WEEK REFILL REGIMEN FOR THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB I... | |||||||||||||
| Medical condition: Neovascular age-related macular degeneration (nAMD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-001182-27 | Sponsor Protocol Number: CRFB002ADE27 | Start Date*: 2014-08-27 | |||||||||||
| Sponsor Name:Novartis Pharma GmbH | |||||||||||||
| Full Title: A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until stu... | |||||||||||||
| Medical condition: Visual impairment due to neovascular AMD | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
